Loading stock data…
MNKD
$3.36-0.16 (-4.55%)
After Hours$3.40+0.04 (+1.19%)· Last close May 11
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
MannKind Corporation in the Healthcare sector is trading at $3.36. The stock is currently 48% below its 52-week high of $6.51, remaining 27.0% below its 200-day moving average. Technical signals show overbought RSI of 73 and bullish MACD crossover, explaining why MNKD maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 73) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.36
Potential Downside
96.2%
Whystock Fair Value$0.13
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$846.10M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
137.00
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.04
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-64.28%
Volume
Today's trading volume
7.53M
Recent News
H.C. Wainwright and Wells Fargo Lift MannKind (MNKD) Price Targets
MannKind Corporation (NASDAQ:MNKD) is one of the 10 Best US Stocks Under $5 to Buy. On May 7, H.C. Wainwright increased its price target on MannKind Corporation (NASDAQ:MNKD) from $8 to $10 and kept its Buy rating on the stock. The research firm noted that MannKind Corporation’s (NASDAQ:MNKD) first-quarter results came in below expectations, but […]
MannKind (MNKD) Is Up 25.4% After Mixed Q1 Results and Expanded United Therapeutics Partnership – What's Changed
MannKind Corporation reported past first-quarter 2026 results with revenue rising to US$90.17 million from US$78.35 million, but the company moved from a US$13.16 million net profit to a US$16.62 million net loss as expenses increased following the scPharmaceuticals acquisition. Alongside these mixed results, MannKind highlighted progress on Afrezza pediatrics, Furoscix ReadyFlow, and an expanded ralinepag DPI collaboration with United Therapeutics that could materially influence its future...
MannKind Q1 Earnings Call Highlights
MannKind (NASDAQ:MNKD) executives used the company’s first-quarter 2026 earnings call to highlight a strengthening collaboration with United Therapeutics, two near-term FDA decision dates, and continued investment in commercial infrastructure following the scPharmaceuticals acquisition. United Ther
MannKind Corporation Q1 2026 Earnings Call Summary
Moby summary of MannKind Corporation's Q1 2026 earnings call
Compared to Estimates, MannKind (MNKD) Q1 Earnings: A Look at Key Metrics
The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.